HUMAN BRAIN MAPPING: FC and structural connection measurement based on EEG and DTI help to study the posture control mechanism of traumatic brain injury
Time of Update: 2021-07-30
Compared with HC, the EEG measurement results of TBI showed the changes in baseline and task modulation of NS, GE, and global graph theory measurement of the modularization of brain function networks .
Blood: Fc-RIIA expression aggravates lupus nephritis and promotes plate plateboard resuscing
Time of Update: 2021-01-15
in a newly established mouse model based on plate activation of IC-Fc-RIIA mediated human SLE, bone marrow cell expression Fc-RIIA significantly aggravated lupus nephritis and accelerated mouse death.
FRET-Based Imaging of Rac and Cdc42 Activation During Fc-Receptor-Mediated Phagocytosis in Macrophages
Time of Update: 2020-11-22
This chapter describes FRET microscopy methods to image the distribution of GTP-bound Rac and Cdc42 during the well-defined morphological transitions of phagocytosis by macrophages.
Blood: Fc-RIIA expression can aggravate nephritis and plateroid intensification of SLE.
Time of Update: 2020-09-02
, in genetically modified mice, Fc?RIIA is expressed in bone marrow cells, significantly exacerbating lupus nephritis and accelerating death.
The oligogloopolymerization of rod-virus cortex protein GP41 is necessary for BV/ODV assembly
Time of Update: 2020-08-10
, entitled The functional oliric state of the teessentialgument protein 41 is for the baculovirus BV and ODV assembly ("The concentration of rod-like viral skin protein GP41 is necessary for BV/ODV assembly). rod virus is a class of large DNA viruses
CAR-T Killer! FDA approved CD19 target new Fc optimized immune-enhanced antibody Monjuvi, the treatment of B-cell tumors is strong!
Time of Update: 2020-08-06
or refractable diffuse large B-cell lymphoma (r/r DLBCL) patients who are not suitable for an autonomous stem cell transplant (ASCT), including DLBCL derived from low-level lymphoma. based on Total Remission Rate (ORR) data, Monjuvi has received FDA
"Optimized Edition" Herceptin! FC optimized immune-enhanced antibody margetuximab treatment
Time of Update: 2020-07-17
!--webeditor: "page title" - - July 11, 2020 /PRNewswire/ -- Reding Pharmaceutical Partners MacroGenics recently announced the evaluation of HER2 target antibody margetuximab in conjunction with Mercaiton anti-PD-1 therapy Keytruda (Coreda, generic
CD19 Targets New Fc Optimized Immune Enhancement Monoantid Tafasitamab To Apply for Listing in the U.S.
Time of Update: 2020-06-17
Recently, MorphoSys announced that it had filed a patentasitamab (MOR208) biologics licensing application (BLA) with the U.S. Food and Drug Administration (FDA) to treat patients with recurrent or refractive diffuse large B-cell lymphoma (r/r DLBCL).
FC-optimized HER2 single-fight Margetuximab treats stomach cancer, receives FDA award for orphan drug
Time of Update: 2020-06-16
Photo Source: Margetuximab is currently in a Phase 2/3 clinical trial maHOGANY (NCT04082364) to evaluate its potential as a first-line therapy for patients with HER2-positive gastric cancer (GC) or gastroesophageal connectivity (GEJ) in combination with immunocheckpoint inhibitors, with/without chemotherapy.
Blood: Effect of human-derived Fc receptor non-binding anti-CD3 monoclonal antibodies in T-ALL
Time of Update: 2020-06-16
Although immunotherapy has greatly improved the treatment of B-ALL and other B-cell malignancies, they have not yet been applied to T-ALL.
of rheumatoid arthritis, better than CTLA-4-Fc fusion protein abatacept
Time of Update: 2020-06-16
At the 2020 European Rheumatology Alliance Annual Meeting (EULAR 2020), AbbVie announced the latest data from the third select-CHOICE clinical trial, which showed that its JAK1 inhibitor, RINVOQ (upadacitinib), reached a major end point of non
After receiving $100 million in financing, Rongchang Bio's fusion protein TACI-Fc treatment of lupus lupus gets FDA fast-track designation
Time of Update: 2020-05-29
RemeGen announced that the U.S. Food and Drug Administration (FDA) has granted fast-track designations for its new recombinant TACI-Fc fusion protein RC18 to treat systemic lupus erythematosus (SLE).
CAR-T Killer! CD19 target new Fc-optimized immuno-enhanced monotafasitamab EU entry review, the treatment of B cell tumor efficacy is strong!
Time of Update: 2020-05-28
May 25, 2020 / Biovalley BIOON/ -- MorphoSys and Incyte recently jointly announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) of Tafasitamab (MOR208), the MA A seeks
The Fc fusion protein injection of recombinant human immunoglobulin ε and γ, a new class 1 new drug
Time of Update: 2020-04-03
Kexin pharmaceutical will strictly implement the requirements of the current clinical trial specifications, organize domestic excellent clinical research team, steadily promote clinical trials, and promote the early approval of the recombinant fusion protein AAFP for the treatment of allergic diseases.
Car-t cell therapy killer! CD19 targeting a new type of FC optimized immunoenhancer monoclonal
Time of Update: 2019-12-28
December 28, 2019 / BIOON / -- morphasys is a clinical German biopharmaceutical company dedicated to developing innovative and differentiated therapies for critical patients
Tianjing biology and Shiyao group reached strategic cooperation on the development of the project of recombinant GLP-1 Fc fusion protein
Time of Update: 2018-12-18
The strategic cooperation includes that Tianjing biology grants the exclusive right to develop the long-term recombinant glp-1fc fusion protein (tg103) in China to Baike (Shandong) biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Shiyao group.
Kangningjierui recombinant CTLA-4 variant Fc fusion protein injection obtained clinical approval
Time of Update: 2017-10-09
Source: Kangning Jierui 2017-10-09 read the clinical approval of CFDA for the recombinant CTLA-4 variant Fc fusion protein injection (moderate to severe rheumatoid arthritis indication) developed by Suzhou Kangning Jierui Biotechnology Co., Ltd.
TNF α monoclonal antibody and rhTNF α: FC domestic declaration and inventory
Time of Update: 2016-12-19
1、 List of domestic applications: Note: cimzia from UCB and simponi from Johnson & Johnson are also under application
In addition, koningjeri kn002 is a biological
FC stone predicts crop production in the United States
Time of Update: 2001-09-07
Introduction: FC stone released its forecast on us crop production on Wednesday
The company predicted that the total soybean production in 2001 / 02 was 2.743 billion